Finding the right product doesn’t have to be overwhelming or expensive. To help you, the Meenta marketplace brings together the widest array of diagnostic products and laboratory services combined with world-class scientific expertise and clinical oversight all in one place. If you have questions, we have answers, just ask us!
Pre-travel Testing for Games In Japan: Lucira All-In-One COVID-19 Test Kit + Physician Oversight
Meenta is proud to support you as the ONLY virtual testing site approved by the government of Japan for pre-travel COVID-19 testing. Thousands of people are already using this product to compete and attend the competitions in Tokyo, Japan.
This product is currently on back-order.
Enter your email below to get notified when this item is back in stock:
Out of stock
Welcome to the ONLY virtual testing site approved by the government of Japan for pre-travel COVID-19 testing!
Meenta is proud to support you on your road to the competitions in Japan as an official virtual testing site for COVID-19. To get the COVID-19 test results report for travel to Japan, purchase this product and look for an email with instructions for getting the PDF results report that can get you to Japan. This will include taking the Point of Care Lucira COVID-19 All in One test, which provides PCR quality molecular accuracy in 30 minutes or less. Sample collection instructions will come by mail with your test kit. Please read these instructions very carefully. Then, you will have to access your Meenta Testing account to upload two photos and answer a few questions to get your full PDF results report (online instructions here).
- FDA/EUA: The first FDA EUA authorized single-use molecular POC test.
- Accuracy: In clinical evaluation, the Positive Percent Agreement (PPA) was 94.1% and the Negative Percent Agreement (NPA) was 98.0%.
- Fast Results: Results in as fast as 11 minutes for a positive result and 30 minutes for a negative result.
- Medical Oversight: This test includes medical oversight and results reporting suitable to gain entry to the Tokyo games.
If you are not associated with the Tokyo games, please see the following alternative products:
The games in Tokyo await you!
The Lucira COVID-19 All-In-One Test Kit is a single-use test kit intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19. This test is authorized for prescription home use with self-collected nasal swab samples in individuals aged 14 and older who are suspected of COVID-19 by their healthcare provider. This test is authorized for use at the Point of Care (POC), in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation, for individuals aged 14 and older, and in individuals aged 13 and under when the specimen is collected by a healthcare provider at the POC. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA in individuals with known or suspected COVID-19. This product does not include the LUCI Pass software.
Variant Detection Information (last updated July 1st, 2021)
The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have highlighted the emergence of four notable SARS-CoV-2 Variants of Concern (1,2):
- Alpha (also known as B.1.1.7) first detected in UK,
- Beta (also known as B.1.351) first detected in South Africa,
- Delta (also known as B.1.617.2) first detected in India,
- Gamma (also known as P.1) first detected in Japan/Brazil, Additionally, a Variant of Interest has been identified to be rising in prevalence:
- Lambda (also known as C.37) first detected in Peru
Lucira Health performs routine surveillance of emerging SARS-CoV-2 strains by periodically evaluating in silico reactivity against sequence databases. These evaluations have shown that these variants are reactive to the Lucira COVID-19 Check-It and All-In-One Test Kits. The Lucira Health assay targets two non-overlapping regions of the N gene. Hence the detection region is unaffected by the mutations in the spike protein of SARS-CoV-2 in the variant strains. As these particular viral strains become commercially available, Lucira Health intends to perform testing to confirm detection of these strains. Lucira Health will continue to monitor the situation with emerging variants of SARS-CoV-2. If you have any questions on the above, please reach out to Technical Support at firstname.lastname@example.org.
2) https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—29-june- 2021
- Credit Card
- HSA Card
- PO Number
Note: These products and services are not returnable.